These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 25517448)

  • 1. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X; Foj L
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL; Ye DW; Zhu Y; Zhang HL; Wang YX; Yao XD
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Iwata T; Kawauchi A; Miki T; Fors Z
    Int J Urol; 2011 Mar; 18(3):200-5. PubMed ID: 21332814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.